Akèy › Fibroz Pulmonè Idyopatik
Etid klinik pou Fibroz Pulmonè Idyopatik ap rekrite nan Etazini
27 etid pou Fibroz Pulmonè Idyopatik ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Birmingham, AL9 etid
- New York City, NY8 etid
- Kansas City, KS7 etid
- Los Angeles, CA7 etid
- Philadelphia, PA7 etid
- Durham, NC6 etid
- Chicago, IL6 etid
- Aurora, CO6 etid
- Dallas, TX5 etid
- Nashville, TN5 etid
- Detroit, MI5 etid
- Atlanta, GA5 etid
- Charleston, SC5 etid
- Houston, TX5 etid
- Salt Lake City, UT4 etid
- Newport Beach, CA4 etid
- Baltimore, MD4 etid
- Oklahoma City, OK4 etid
- Ann Arbor, MI4 etid
- Winston-Salem, NC4 etid
- El Paso, TX4 etid
- Pittsburgh, PA3 etid
- Boston, MA3 etid
- Champaign, IL3 etid
- Greensboro, NC3 etid
- Denver, CO3 etid
- Denison, TX3 etid
- Charlottesville, VA3 etid
- Orlando, FL3 etid
- Arlington, VA3 etid
- Richmond, VA3 etid
- Mountain View, CA3 etid
- New Haven, CT3 etid
- Cincinnati, OH3 etid
Pa eta
- Alabama9 etid
- Arizona5 etid
- Colorado9 etid
- Connecticut4 etid
- Florid10 etid
- Georgia5 etid
- Illinois8 etid
- Kalifòni12 etid
- Kansas7 etid
- Kentucky3 etid
- Lwizyàn4 etid
- Maryland4 etid
- Massachusetts4 etid
- Michigan7 etid
- Missouri6 etid
- New York8 etid
- North Carolina10 etid
- Ohio5 etid
- Oklahoma4 etid
- Oregon3 etid
- Pennsylvania12 etid
- South Carolina8 etid
- Tennessee6 etid
- Texas11 etid
- Utah5 etid
- Virginia8 etid
- Wisconsin3 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06951217A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
Ap rekriteFaz 2
Laj 40 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT07652658A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis
Ap rekriteFaz 2
Laj 40 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07516951Pulmonary Fibrosis Foundation Community Registry
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT05382572RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Sep 15, 2026 · NCT07002034Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets
Ap rekriteFaz 3
Laj 40 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT07671911A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
Ap rekriteFaz 2
Laj 40 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT06968845Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
Ap rekriteFaz 2
Laj 40 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT07230288Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)
Ap rekriteFaz 3
Laj 40 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT07284602Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Ap rekriteFaz 2
Laj 40 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT05571059Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF)
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 27, 2026 · NCT00373841Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
Ap rekriteEtid obsèvasyon
Laj 21 ak plis · Tout sèks · Mizajou Aug 12, 2026 · NCT01915511Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis
Ap rekriteFaz 1
Laj 40 a 85 · Tout sèks · Mizajou Aug 12, 2026 · NCT04362644Dose-Escalation Study of Artesunate Patients With IPF
Ap rekriteFaz 1
Laj 40 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT05988463WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Ap rekriteFaz 2
Laj 40 ak plis · Tout sèks · Mizajou Aug 10, 2026 · NCT06967805H01 in Adults With Interstitial Lung Disease (The SOLIS Study)
Ap rekriteFaz 2
Laj 18 a 100 · Tout sèks · Mizajou Jul 28, 2026 · NCT06325696Interstitial Lung Disease Research Unit Biobank
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jul 10, 2026 · NCT05392881A Study of the Natural Progression of Interstitial Lung Disease (ILD)
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Jun 9, 2026 · NCT00470327Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease
Ap rekriteEtid obsèvasyon
Laj 45 a 90 · Tout sèks · Mizajou May 1, 2026 · NCT03297775Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure
Ap rekriteFaz 1/2
Laj 18 a 60 · Tout sèks · Mizajou Jan 13, 2026 · NCT03500731Mechanisms of Familial Pulmonary Fibrosis
Ap rekriteEtid obsèvasyon
Laj 40 a 75 · Tout sèks · Mizajou Dec 31, 2025 · NCT03437486Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Nov 14, 2025 · NCT01776398Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
Ap rekriteFaz 2
Laj 40 ak plis · Tout sèks · Mizajou Nov 12, 2025 · NCT05975983Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis
Ap rekriteFaz 2
Laj 50 ak plis · Tout sèks · Mizajou Nov 10, 2025 · NCT06567717Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis
Ap rekriteFaz 1 bonè
Laj 18 ak plis · Tout sèks · Mizajou Jul 9, 2025 · NCT06853145Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.